REG - Beximco Pharmaceut - Board Change

Beximco PharmaceuticalsAnnouncement

30/07/2020 07:00

RNS Number : 5379U
  
Beximco Pharmaceuticals Ltd
  
30 July 2020
  
 

30 July 2020
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
BEXIMCO PHARMACEUTICALS LTD. 
 
Board Change
 
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces it has appointed Professor Mamtaz Uddin Ahmed as an Independent Non-Executive Director with immediate effect. 
 
Professor Ahmed has over 35 years' teaching experience in finance and he is currently Professor of the Department of Accounting and Information Systems, and Chairman of the Bureau of Business Research, at the University of Dhaka, Bangladesh. Professor Ahmed is also an experienced board member, currently holding senior positions in the medical device company, Sysmark Ltd., and the Bangladesh government-owned power company, Ashuganj Power Station Company Ltd. His previous board positions include Director of the Chittagong Stock Exchange Ltd. and Director of the Dhaka Stock Exchange Ltd. In addition, Professor Ahmed is the Vice President of the South Asian Federation of Accountants and the former President of the Institute of Cost and Management Accountants of Bangladesh.
 
Mr. A S F Rahman, Chairman of the Board of Directors of Beximco Pharmaceuticals, commented:  
 
"I am delighted that Professor Ahmed has agreed to join the Board. He brings an impressive level of boardroom experience and financial knowledge, which will be invaluable to the Company as we continue to implement our growth strategy across the domestic and international markets."
 
Additional disclosure information
 
Save for the information in this announcement, there are no further disclosures to be made in accordance with Schedule Two (g) of the AIM Rules for Companies in respect of the appointments of Professor Mamtaz Uddin Ahmed.
 
In addition to his appointment to the Board, Professor Mamtaz Uddin Ahmed, aged 62, holds or has held the following directorships or partnerships in the past five years:
 



Current directorships/partnerships:
Ashuganj Power Station Company Ltd.
Sysmark Ltd.
 


Previous directorships/partnerships:
Chittagong Stock Exchange Ltd.
Dhaka Power Distribution Company Ltd.
 



 
Professor Mamtaz Uddin Ahmed does not have any direct and indirect interest in the issued share capital of the Company.
 
For further information please visit www.beximcopharma.com or enquire to: 
 



Beximco Pharma




Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
 




Mohammed Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, ext.20030
 




Jamal Ahmed Choudhury, Executive Director (A&F)
Tel: +880 2 58611001, ext.20022
 




SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
 




SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
 




FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
 



 
Notes to Editors
 
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
 
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
BOARLMMTMTTTTPM